HSPB1 and hyperlipidemia: Researchers found that Valdecoxib (VAL) can inhibit inflammation and endoplasmic reticulum (ER) stress through AMPK-regulated HSPB1 pathway, thus improving skeletal muscle IR under hyperlipidemia.501 The insulin signal described above has a key role in AD pathogenesis.